Kodiak Sciences (KOD) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Vaxcyte (PCVX) over the past year, gaining 367.8% versus a gain of 15.9%. Over five years, PCVX leads with a +178.9% price change compared with +3.0% for KOD. Vaxcyte is the larger company by market cap ($8.77 billion vs $6.35 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KOD | PCVX |
|---|---|---|
| Share price | $97.17 | $55.39 |
| Market cap | $6.35B | $8.77B |
| 1-day change | -0.75% | -5.09% |
| YTD return | +247.53% | +20.05% |
| 1-year return | +367.84% | +15.93% |
| 5-year return | +3.04% | +178.90% |
| EPS (TTM) | $-4.08 | $-8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-229.97M | $-766.63M |
| 52-week high | $112.79 | $90.75 |
| 52-week low | $20.38 | $42.40 |
| Distance from 52-week high | -13.85% | -38.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +33.27% | +110.15% |
| Average volume | 1.77M | 2.19M |
| Shares outstanding | 65.40M | 158.30M |
| Employees | 144 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed PCVX by 351.9 percentage points over the past year.
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
KOD vs PCVX FAQ
Which is bigger, Kodiak Sciences or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $6.35B for Kodiak Sciences (KOD).
Which stock has performed better over the past year, KOD or PCVX?
KOD returned +367.84% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Kodiak Sciences and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.